Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage biopharmaceutical company that designs immune-stimulating antibody conjugates (ISACs) — tumour-targeting antibodies linked to TLR7/8 agonist payloads that activate myeloid cells inside the tumour microenvironment. Its Boltbody platform generated BDC-4182, a claudin 18.2-directed ISAC in Phase 1/2, while most of the earlier pipeline was placed on hold during a 2025 restructuring. In October 2026 the company acquired Prana Therapies in a stock-for-stock reverse merger alongside a $120 million private placement, refocusing the enterprise on PRA-216 in inflammatory disease.